Form 4: Amicus Therapeutics CEO Sells Shares After Option Exercise
Insider Transaction Report
Amicus Therapeutics President and CEO, Bradley L. Campbell, exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.
Summary
- Bradley L. Campbell, President and CEO of Amicus Therapeutics, Inc. (FOLD), reported transactions on December 15, 2025.
- Exercised 70,426 stock options at an exercise price of $9.03 per share, which were fully vested and exercisable.
- Subsequently sold 77,926 shares of common stock at a weighted average price of $10.8566 per share, with individual sale prices ranging from $10.60 to $11.11.
- All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these transactions, beneficial ownership stands at 1,129,782 shares of Amicus Therapeutics common stock held directly.
Sentiment
Score: 5
Explanation: The filing reports a standard insider transaction involving the exercise of stock options and subsequent sale of shares under a Rule 10b5-1 trading plan, which is a common practice for executives. It does not inherently signal a strong positive or negative outlook for the company.
Positives
- The exercise of stock options indicates that the insider saw value in converting options to shares.
- The sale price ($10.8566 average) was higher than the exercise price ($9.03), resulting in a profitable transaction for the insider.
Negatives
- The number of shares sold (77,926) exceeded the number of options exercised (70,426), resulting in a net reduction of 7,500 shares in direct beneficial ownership from the pre-exercise level.
- Insider selling, even under a pre-arranged 10b5-1 plan, can sometimes be perceived negatively by some investors, although the pre-scheduled nature mitigates this concern.
Future Outlook
No forward-looking statements or guidance are provided in this filing, as it reports past insider transactions.
Industry Context
This filing is a routine disclosure of insider trading activity and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding executive stock ownership changes, which can influence investor sentiment, though the 10b5-1 plan mitigates immediate concerns.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Rule 10b5-1 trading plan adopted by Bradley L. Campbell. |
| 12/15/2025 | Date of stock option exercise and subsequent sale of common stock. |
| 01/04/2026 | Expiration date of the exercised stock options. |
Keywords
Amicus Therapeutics, FOLD, Insider Trading, Form 4, Stock Options, CEO, Share Sale, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.